ABSTRACT The objective of this study is to investigate the impact of valsartan versus valsartan-hydrochlorothiazide on the lipid profile parameters in hypertensive patients in comparison with control. Healthy control and hypertensive patients of either sex participated in this study; they were assigned into three groups (of twenty-three subjects each). Group 1 was the control group. Group 2 comprised of hypertensive patients treated with valsartan and Group 3 comprised of hypertensive patients treated with valsartan-hydrochlorothiazide (valsartan-HCT) combination once a day with a dose of 80 mg or 160 mg and 80/12.5 mg or 160/12.5 mg or 160/25 mg (the duration was not less than 3 months), respectively. Blood samples were collected from each subject and then the parameters of the lipid profile were measured in both control and hypertensive patients using a biochemical analysis. Systolic and diastolic blood pressure in patients treated with valsartan and valsartan-HCT drugs were significantly higher than that of the control group. In treated groups, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and total cholesterol (TC) were significantly higher than those of the control group. However, in the valsartan-HCT group, high-density lipoprotein cholesterol (HDL-C) was significantly lower than that of the control group, while in the valsartan group, high-density lipoprotein cholesterol (HDL-C) was non-significantly lower than that of the control group. This study confirmed that the treatment with valsartan and valsartan-HCT may not control the blood pressure and that the drugs may interfere with lipid profile. Hence, a readjustment of the therapy is important.
View Full Article
|